Literature DB >> 33742092

Metabolic changes of Interleukin-12/15/18-stimulated human NK cells.

Iñigo Terrén1, Ane Orrantia1, Alba Mosteiro1, Joana Vitallé1, Olatz Zenarruzabeitia2, Francisco Borrego3,4.   

Abstract

Natural Killer (NK) cells acquire memory-like properties following a brief stimulation with IL-12, IL-15 and IL-18. These IL-12/15/18-preactivated NK cells, also known as cytokine-induced memory-like (CIML) NK cells, have been revealed as a powerful tool in cancer immunotherapy due to their persistence in the host and their increased effector functions. Several studies have shown that NK cells modulate their metabolism in response to cytokine-stimulation and other stimuli, suggesting that there is a link between metabolism and cellular functions. In this paper, we have analyzed metabolic changes associated to IL-12/15/18-stimulation and the relevance of glycolytic pathway for NK cell effector functions. We have found CIML NK cells are able to retain a metabolic profile shifted towards glycolysis seven days after cytokine withdrawal. Furthermore, we found that treatment with 2-DG differently affects distinct NK cell effector functions and is stimuli-dependent. These findings may have implications in the design of NK cell-based cancer immunotherapies.

Entities:  

Year:  2021        PMID: 33742092     DOI: 10.1038/s41598-021-85960-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  46 in total

Review 1.  Current progress in NK cell biology and NK cell-based cancer immunotherapy.

Authors:  Raquel Tarazona; Nelson Lopez-Sejas; Beatriz Guerrero; Fakhri Hassouneh; Isabel Valhondo; Alejandra Pera; Beatriz Sanchez-Correa; Nieves Pastor; Esther Duran; Corona Alonso; Rafael Solana
Journal:  Cancer Immunol Immunother       Date:  2020-03-04       Impact factor: 6.968

2.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Authors:  Kevin C Conlon; Enrico Lugli; Hugh C Welles; Steven A Rosenberg; Antonio Tito Fojo; John C Morris; Thomas A Fleisher; Sigrid P Dubois; Liyanage P Perera; Donn M Stewart; Carolyn K Goldman; Bonita R Bryant; Jean M Decker; Jing Chen; Tat'Yana A Worthy; William D Figg; Cody J Peer; Michael C Sneller; H Clifford Lane; Jason L Yovandich; Stephen P Creekmore; Mario Roederer; Thomas A Waldmann
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

3.  Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Authors:  Locke D Uppendahl; Martin Felices; Laura Bendzick; Caitlin Ryan; Behiye Kodal; Peter Hinderlie; Kristin L M Boylan; Amy P N Skubitz; Jeffrey S Miller; Melissa A Geller
Journal:  Gynecol Oncol       Date:  2019-01-15       Impact factor: 5.482

4.  First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

Authors:  Sarah Cooley; Fiona He; Veronika Bachanova; Gregory M Vercellotti; Todd E DeFor; Julie M Curtsinger; Paul Robertson; Bartosz Grzywacz; Kevin C Conlon; Thomas A Waldmann; David H McKenna; Bruce R Blazar; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Blood Adv       Date:  2019-07-09

5.  Percutaneous absorption of uranium compounds.

Authors:  B M de Rey; H E Lanfranchi; R L Cabrini
Journal:  Environ Res       Date:  1983-04       Impact factor: 6.498

6.  Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Authors:  Kim Margolin; Chihiro Morishima; Vamsidhar Velcheti; Jeffrey S Miller; Sylvia M Lee; Ann W Silk; Shernan G Holtan; Andreanne M Lacroix; Steven P Fling; Judith C Kaiser; Jack O Egan; Monica Jones; Peter R Rhode; Amy D Rock; Martin A Cheever; Hing C Wong; Marc S Ernstoff
Journal:  Clin Cancer Res       Date:  2018-07-25       Impact factor: 12.531

7.  A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors.

Authors:  Antonio Pérez-Martínez; Lucía Fernández; Jaime Valentín; Isabel Martínez-Romera; María Dolores Corral; Manuel Ramírez; Lorea Abad; Sandra Santamaría; Marta González-Vicent; Sara Sirvent; Julián Sevilla; José Luis Vicario; Inmaculada de Prada; Miguel Ángel Diaz
Journal:  Cytotherapy       Date:  2015-09-01       Impact factor: 5.414

8.  Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.

Authors:  M Vela; D Corral; P Carrasco; L Fernández; J Valentín; B González; A Escudero; A Balas; R de Paz; J Torres; A Leivas; J Martinez-Lopez; A Pérez-Martínez
Journal:  Cancer Lett       Date:  2018-02-23       Impact factor: 8.679

9.  First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Authors:  Rizwan Romee; Sarah Cooley; Melissa M Berrien-Elliott; Peter Westervelt; Michael R Verneris; John E Wagner; Daniel J Weisdorf; Bruce R Blazar; Celalettin Ustun; Todd E DeFor; Sithara Vivek; Lindsey Peck; John F DiPersio; Amanda F Cashen; Rachel Kyllo; Amy Musiek; András Schaffer; Milan J Anadkat; Ilana Rosman; Daniel Miller; Jack O Egan; Emily K Jeng; Amy Rock; Hing C Wong; Todd A Fehniger; Jeffrey S Miller
Journal:  Blood       Date:  2018-02-20       Impact factor: 25.476

10.  Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

Authors:  Jing Ni; Matthias Miller; Ana Stojanovic; Natalio Garbi; Adelheid Cerwenka
Journal:  J Exp Med       Date:  2012-12-03       Impact factor: 14.307

View more
  5 in total

Review 1.  Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications.

Authors:  Iñigo Terrén; Ane Orrantia; Gabirel Astarloa-Pando; Ainhoa Amarilla-Irusta; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 2.  Cytokine-induced memory-like natural killer cells for cancer immunotherapy.

Authors:  Mubin Tarannum; Rizwan Romee
Journal:  Stem Cell Res Ther       Date:  2021-12-04       Impact factor: 6.832

3.  Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity.

Authors:  Nidhi Kedia-Mehta; Laura Tobin; Vanessa Zaiatz-Bittencourt; Marta M Pisarska; Conor De Barra; Chloe Choi; Einas Elamin; Donal O'Shea; Clair M Gardiner; David K Finlay; Andrew E Hogan
Journal:  Blood Adv       Date:  2021-11-09

Review 4.  Overcoming tumor resistance mechanisms in CAR-NK cell therapy.

Authors:  Antonio Valeri; Almudena García-Ortiz; Eva Castellano; Laura Córdoba; Elena Maroto-Martín; Jessica Encinas; Alejandra Leivas; Paula Río; Joaquín Martínez-López
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

Review 5.  Stem Cell Therapy and Innate Lymphoid Cells.

Authors:  Divya Verma; Mukesh Verma; Rangnath Mishra
Journal:  Stem Cells Int       Date:  2022-08-02       Impact factor: 5.131

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.